✦ LIBER ✦

Prophylaxis of central nervous system leukemia: a case of chronic myeloid leukemia with lymphoid blast crisis treated with imatinib mesylate

✍ Scribed by Vasantha Thavaraj; Rachna Seth

Publisher: SP Children’s Hospital, Zhejiang University School of Medicine
Year: 2008
Tongue: English
Weight: 86 KB
Volume: 4
Category: Article
ISSN: 1708-8569
DOI: 10.1007/s12519-008-0029-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Central Nervous System Blast Crisis in C

Central Nervous System Blast Crisis in Chronic Myeloid Leukemia on Imatinib Mesylate Therapy: Report of Two Cases

✍ Narayan Radhika; Mishra Minakshi; Mohanty Rajesh; Baisakh R. Manas; Mishra Deepa 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 214 KB

Central nervous system blastic crisis in

Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report

✍ Abdullah Altintas; Timucin Cil; Ilhan Kilinc; Muhammet Ali Kaplan; Orhan Ayyildi 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 165 KB

Efficacy and prognosis of chronic myeloi

Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population

✍ Yanmin Zhao; Lizhen Liu; Yingjia Wang; Gongqiang Wu; Xiaoyu Lai; Weijie Cao; Yi 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 280 KB

A case of chronic myeloid leukemia with

A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11

✍ Koichiro Suemori; Hiroshi Fujiwara; Seiichiro Watanabe; Taichi Azuma; Masaki Yas 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 173 KB

Chronic lymphocytic leukemia with centra

Chronic lymphocytic leukemia with central nervous system involvement: report of two cases with a comprehensive literature review

✍ Alan A. Moazzam; Jan Drappatz; Ryan Y. Kim; Santosh Kesari 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 287 KB

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o